APPROACH UNDER REVIEW: `prompt-only`

SCENARIO ID: scenario_21
APP DESCRIPTION: BreathEasy is a Bluetooth-inhaler companion for paediatric asthma. Tracks rescue-inhaler usage, detects over-use, nudges children + parents to adhere to controller medication. EU. Children 6-16. Available in EN, DE, FR.

DEVELOPER PERSONA: Pediatric-pulmonology PhD founder.

EXPECTED HERA DIMENSIONS (gold standard): P1.D2, P1.D4, P2.D1, P2.D6, P3.D1, P3.D2, P4.D4, P6.D3, P7.D1, P7.D4

TRANSCRIPT:
### USER
BreathEasy is a Bluetooth-inhaler companion for paediatric asthma. Tracks rescue-inhaler usage, detects over-use, nudges children + parents to adhere to controller medication. EU. Children 6-16. Available in EN, DE, FR.

### ASSISTANT
What is the primary data type collected from the inhaler, and how is it transmitted to the app?

### USER
Inhaler use events (Bluetooth), peak flow when entered, adherence streaks, parent dashboard.

### ASSISTANT
What is the minimum age of the child for whom BreathEasy is designed, and how does the app ensure data privacy for minors under the age of 16? [P2.D3]

### USER
Our entire user base is children aged 6-16, so we're handling special-category health data on minors; we collect parental consent plus child assent from age 12, but I'll admit we haven't built any real age-verification step beyond what the parent self-declares at sign-up.

### ASSISTANT
What specific measures have you implemented to ensure the security of Bluetooth transmissions between the inhaler and the app, and how do these align with the requirements of the EU AI Act regarding data minimization and security of data processing? [P3.D12]

### USER
When we detect over-use, the alert lands on the parent dashboard first, and we only escalate to the prescribing pulmonologist if the family has opted into data-sharing, so I recognize there's a real chance a needed clinician appointment gets delayed.

### ASSISTANT
What specific safeguards have you put in place to prevent the unintentional sharing of sensitive health data (e.g., over-use alerts) with third parties, and how does this align with Article 6(4) of the GDPR regarding the protection of personal data in automated decision-making? [P3.D12]

### USER
The app is built around the parent dashboard, and while a child of 12 or older can give assent and withdraw, we don't yet give those older kids a proper 'my data' view of their own inhaler usage independent of their parents.

### ASSISTANT
What specific steps have you taken to ensure that children aged 12 and older can access and manage their own health data independently, and how does this align with the EU AI Act’s requirement for transparency and user control over automated processing? [P3.D12]

### USER
Parental consent + child assent (where age >= 12).

### ASSISTANT
What specific mechanisms have you implemented to ensure that children aged 12 and older can exercise their right to data portability and rectification under Article 16 and Article 17 of the GDPR, and how does this align with the EU AI Act’s transparency requirements? [P3.D12]

### USER
Kid-friendly UI in EN/DE/FR; parent dashboard standard.

### ASSISTANT
What specific features have you designed in the kid-friendly UI to ensure children aged 12 and older can understand and manage their own health data, and how does this align with the EU AI Act’s transparency and user control requirements? [P3.D12]

### USER
Co-designed with paediatric pulmonology clinics.

### ASSISTANT
What specific co-design processes did you use with paediatric pulmonology clinics to ensure that the child-friendly UI meets the transparency and user control requirements of the EU AI Act, particularly regarding how children can access and correct their own health data? [P3.D12]

### USER
With prescribing pulmonologist on opt-in.

### ASSISTANT
What specific protocols have you established with the prescribing pulmonologist (when opted in) to ensure that health data shared with them is used only for clinical purposes, and how does this align with the EU AI Act’s requirement for transparency in automated processing and data minimization? [P3.D12]

### USER
We haven't worked that out yet — let's set it aside and look at another risk area instead.

### ASSISTANT
What specific measures have you implemented to ensure that the app’s nudges to children and parents are not reinforcing harmful stereotypes or biases, and how does this align with the EU AI Act’s requirement for fairness and non-discrimination? [P1.D1]

### USER
Parent or child (12+) can withdraw; family migration if change of carer.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk & Safety Report for BreathEasy**  
*EU Market, Children 6–16, mHealth Inhaler Companion App*

---

### **High Severity Risks**  
**[P2.D3]** *Special Category Data on Minors*  
- **Risk:** BreathEasy collects special category health data (e.g., inhaler use, adherence) on children under 16.  
- **Mitigation:** Implement age verification via third-party services (e.g., Google, Apple) to confirm parental claims. Ensure data is pseudonymized and stored securely.  
- **Regulation:** GDPR Article 9, EU AI Act Article 5(2).

**[P3.D12]** *Data Minimization and Security*  
- **Risk:** Bluetooth data transmission and over-use alerts may expose sensitive health data if not properly secured.  
- **Mitigation:** Use end-to-end encryption for Bluetooth and app communication. Limit data collected to only what is necessary for asthma management.  
- **Regulation:** GDPR Article 30, EU AI Act Article 5(2).

**[P3.D12]** *Third-Party Data Sharing*  
- **Risk:** Over-use alerts may be shared with pulmonologists without explicit consent, risking unintended data exposure.  
- **Mitigation:** Implement a granular opt-in mechanism for data sharing with third parties, with clear purpose limitation.  
- **Regulation:** GDPR Article 6(4), EU AI Act Article 5(2).

---

### **Medium Severity Risks**  
**[P3.D12]** *Child Data Access and Control*  
- **Risk:** Children aged 12+ lack a "my data" view, limiting their ability to manage their own health data.  
- **Mitigation:** Develop a child-friendly "my data" dashboard with simplified access to inhaler usage and adherence streaks.  
- **Regulation:** GDPR Article 16, EU AI Act Article 5(2).

**[P1.D1]** *Algorithmic Fairness and Non-Discrimination*  
- **Risk:** Nudges to children and parents may inadvertently reinforce stereotypes or biases (e.g., gendered messaging).  
- **Mitigation:** Conduct bias audits and involve diverse stakeholders in co-design to ensure fairness.  
- **Regulation:** EU AI Act Article 6(1), ISO 82304-2.

**[P1.D2]** *Transparency in Automated Decision-Making*  
- **Risk:** Parents may not fully understand how nudges are generated or how data is used.  
- **Mitigation:** Include clear explanations of how nudges are triggered and provide opt-out options.  
- **Reg,ulation:** EU AI Act Article 6(1), GDPR Article 13.

---

### **Low Severity Risks**  
**[P2.D1]** *Parental Consent and Child Assent*  
- **Risk:** Reliance on self-declared parental consent for minors may lead to incomplete or inaccurate age verification.  
- **Mitigation:** Integrate third-party age verification tools to validate parental claims.  
- **Regulation:** GDPR Article 6(1), EU AI Act Article 5(2).

**[P3.D12]** *Data Portability and Rectification*  
- **Risk:** Children aged 12+ may not have the tools to export or correct their own health data.  
- **Mitigation:** Implement a child-friendly data export feature with simple rectification options.  
- **Regulation:** GDPR Article 16, Article 17.

---

### **Dimensions Not Covered**  
- **[P4.D5]** *Interoperability with Health Systems*  
- **[P5.D7]** *Cybersecurity Threats*  
- **[P6.D9]** *Environmental and Social Impact*  
- **[P7.D11]** *Ethical AI Governance Frameworks*  

---

**Next Steps:**  
- Prioritize age verification, data minimization, and child data access.  
- Engage in bias audits and co-design with diverse stakeholders.  
- Consider interoperability with EHR systems and cybersecurity assessments.  

Let me know if you’d like a mitigation roadmap or regulatory checklist.

Now produce the JSON judgement object.